CYTK

Cytokinetics Inc

A biopharmaceutical company in South San Francisco that develops muscle-directed medicines for heart and muscle diseases. Its approved drug, MYQORZO (aficamten), treats obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and works too hard. Founded in 1997 by four scientists, including Stanford's James Spudich, the company grew out of research on myosin, the motor protein that powers muscle contraction. The name "Cytokinetics" blends "cyto" (cell) and "kinetics" (motion), reflecting the founders' original study of how cells move.

CUSIP: 23282W605HealthcareUS1 holder

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 5 years

Insider

Blum Robert IPresident & CEO, Director · 198 transactions

389.5K+7.7%

Granted 1.17M · Sold 958.0K

Malik Fady IbrahamEVP Research & Development · 188 transactions

157.4K+1.6%

Granted 627.4K · Sold 571.8K

Cragg DavidChief HR & Admin Officer · 16 transactions

153.2K+0.5%

as of Mar 2022

Granted 95.0K · Sold 85.4K

Hessekiel JeffreyChief Legal & Admin Officer · 2 transactions

107.9K—

Granted 107.9K

Schlossberg Mark ASVP - Legal & General Counsel · 11 transactions

98.6K+93.9%

as of Mar 2022

Granted 105.8K · Sold 45.2K

Henderson John TDirector · 50 transactions

78.2K+499.8%

Granted 155.9K · Sold 91.2K

Lee SungEVP, Chief Financial Officer · 27 transactions

65.3K—

Granted 142.8K · Sold 70.7K

Callos AndrewEVP, Chief Commercial Officer · 68 transactions

58.6K—

Granted 338.5K · Sold 268.5K

Jaw ChingSVP Finance & CFO · 19 transactions

57.3K-35.2%

as of Mar 2023

Granted 110.0K · Sold 90.7K

Wierenga WendellDirector · 10 transactions

35.5K—

Granted 31.6K · Sold 28.4K

Wysenski NancyDirector · 23 transactions

33.9K+492.1%

Granted 28.2K

Pletcher Brett AEVP, Chief Legal Officer · 1 transaction

33.1K—

as of Aug 2024

Granted 33.1K

Wierenga WendallDirector · 39 transactions

32.3K+400.8%

as of Jul 2025

Granted 83.2K · Sold 57.3K

Gage L PatrickDirector · 5 transactions

30.8K+1.7%

as of Nov 2021

Granted 27.0K · Sold 26.5K

Bhanji MunaDirector · 12 transactions

26.4K+427.2%

Granted 26.8K · Sold 5.5K

Harrington Robert ArthurDirector · 24 transactions

21.8K—

Granted 29.3K · Sold 7.5K

Costa Santo JDirector · 5 transactions

20.6K+312%

as of May 2024

Granted 25.6K · Sold 10.0K

Smith Sandford DDirector · 28 transactions

18.8K+191.1%

as of Jan 2024

Granted 81.0K · Sold 68.7K

Wong RobertVP, Chief Accounting Officer · 19 transactions

17.9K-25.1%

as of Dec 2024

Granted 21.1K · Sold 20.3K

Parshall B LynneDirector · 40 transactions

15.8K+215.7%

Granted 137.4K · Sold 126.6K

Kaye Edward M. MDDirector · 37 transactions

10.3K+59.2%

Granted 90.3K · Sold 86.4K

Landry Robert EDirector · 2 transactions

10.2K—

Granted 10.2K

Mr. CostaDirector · 3 transactions

10.0K—

as of Sep 2022

Granted 15.0K · Sold 15.0K

Califf RobertDirector · 2 transactions

6.0K+4.8%

as of Jan 2022

Granted 275

Daly James MDirector · 3 transactions

3.2K—

Granted 3.2K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Blum Robert IPresident & CEO, Director · 198 transactions	+7.7%	389.5K	1.17M	—	958.0K
Malik Fady IbrahamEVP Research & Development · 188 transactions	+1.6%	157.4K	627.4K	—	571.8K
Cragg DavidChief HR & Admin Officer · 16 transactions	+0.5%	153.2Kas of Mar 2022	95.0K	—	85.4K
Hessekiel JeffreyChief Legal & Admin Officer · 2 transactions	—	107.9K	107.9K	—	—
Schlossberg Mark ASVP - Legal & General Counsel · 11 transactions	+93.9%	98.6Kas of Mar 2022	105.8K	—	45.2K
Henderson John TDirector · 50 transactions	+499.8%	78.2K	155.9K	—	91.2K
Lee SungEVP, Chief Financial Officer · 27 transactions	—	65.3K	142.8K	—	70.7K
Callos AndrewEVP, Chief Commercial Officer · 68 transactions	—	58.6K	338.5K	—	268.5K
Jaw ChingSVP Finance & CFO · 19 transactions	-35.2%	57.3Kas of Mar 2023	110.0K	—	90.7K
Wierenga WendellDirector · 10 transactions	—	35.5K	31.6K	—	28.4K
Wysenski NancyDirector · 23 transactions	+492.1%	33.9K	28.2K	—	—
Pletcher Brett AEVP, Chief Legal Officer · 1 transaction	—	33.1Kas of Aug 2024	33.1K	—	—
Wierenga WendallDirector · 39 transactions	+400.8%	32.3Kas of Jul 2025	83.2K	—	57.3K
Gage L PatrickDirector · 5 transactions	+1.7%	30.8Kas of Nov 2021	27.0K	—	26.5K
Bhanji MunaDirector · 12 transactions	+427.2%	26.4K	26.8K	—	5.5K
Harrington Robert ArthurDirector · 24 transactions	—	21.8K	29.3K	—	7.5K
Costa Santo JDirector · 5 transactions	+312%	20.6Kas of May 2024	25.6K	—	10.0K
Smith Sandford DDirector · 28 transactions	+191.1%	18.8Kas of Jan 2024	81.0K	—	68.7K
Wong RobertVP, Chief Accounting Officer · 19 transactions	-25.1%	17.9Kas of Dec 2024	21.1K	—	20.3K
Parshall B LynneDirector · 40 transactions	+215.7%	15.8K	137.4K	—	126.6K
Kaye Edward M. MDDirector · 37 transactions	+59.2%	10.3K	90.3K	—	86.4K
Landry Robert EDirector · 2 transactions	—	10.2K	10.2K	—	—
Mr. CostaDirector · 3 transactions	—	10.0Kas of Sep 2022	15.0K	—	15.0K
Califf RobertDirector · 2 transactions	+4.8%	6.0Kas of Jan 2022	275	—	—
Daly James MDirector · 3 transactions	—	3.2K	3.2K	—	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.